Objectives

1. To evaluate study on whether canakinumab might reduce cardiovascular event rates and improve renal function among post-myocardial infarc patients with chronic kidney disease.

2. To determine clinical significance of study results.

Session date: 
10/11/2018 - 1:00pm to 2:00pm CDT
Location: 
UCMC AMB W-507
Chicago, IL 60637
United States
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
Dr. Victoria Vo